Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2881-2900 of 3,900 trials

Brain Metastases Detection: PET-DOPA Imaging Study

We are studying a new imaging method to detect untreated brain metastases in patients with lung, breast, or melanoma cancer. This research aims to improve how we identify and understand these tumors.

Brain Metastases from Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Non-Small Cell Lung Cancer: MB12 vs. Keytruda

We are comparing a new treatment, MB12, to Keytruda for patients with non-small cell lung cancer. The study aims to understand differences in effectiveness and safety between the two options.

Advanced Non-Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Oncology

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyPediatrics

Chickenpox Vaccine Safety Study for Young Children

We are evaluating the safety of a new chickenpox vaccine for healthy children aged 12 to 15 months. This study compares it with an existing vaccine when given with other routine immunizations.

Chickenpox6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Chickenpox Vaccine Study for Children Aged 12 to 15 Months

We are evaluating a new chickenpox vaccine to see how well it works and its safety compared to the standard Varivax vaccine in healthy children. This study aims to ensure that the new vaccine provides a strong immune response.

Chickenpox6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Clindamycin for Infections: Impact of Rifampicin and Obesity

We are studying how body weight and the antibiotic rifampicin affect the effectiveness of clindamycin in treating infections. This research may help improve treatment strategies for patients with varying body types.

Hidradenitis SuppurativaProsthetic Joint InfectionsFracture Related Infections≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Biliary Tract Cancer: Ivonescimab vs. FOLFOX

We are testing a new treatment, ivonescimab, against standard chemotherapy for patients with advanced biliary tract cancer. The goal is to see if it helps patients live longer and feel better.

Advanced Biliary Tract Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: 89Zr-Df-crefmirlimab Imaging Study

We are studying a new imaging method to see how well it shows cancer cells in patients with advanced solid tumors. This may help us understand treatment responses and immune cell activity better.

Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

C3 Glomerulopathy: Aliskiren vs. Enalapril

We are studying whether the medication aliskiren can improve kidney function in people with C3 glomerulopathy compared to the standard treatment, enalapril. This trial aims to assess its safety and effectiveness in reducing kidney disease markers.

C3 Glomerulopathy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesNephrology

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Histiocytosis: Fludeoxyglucose (18F-FDG) Imaging Study

We are examining how fludeoxyglucose (18F-FDG) in PET/CT scans can help monitor juvenile patients with histiocytosis. The study will assess its safety and potential benefits for those with specific mutations.

Erdheim-Chester DiseaseLangerhans Cell SarcomaRosai-Dorfman Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOtolaryngology

Histiocytosis in Children: Trametinib Study

We are testing the safety and effectiveness of trametinib in children with refractory histiocytosis. The goal is to find the best dosage and timing for treatment after other therapies have failed.

Erdheim-Chester DiseaseRosai-Dorfman SyndromeLangerhans' Cell Histiocytosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Posttraumatic Headache: Botulinum Toxin A Study

We are investigating whether botulinum toxin A can safely reduce the number of headache days for individuals with posttraumatic headaches. The study also looks at biological markers to see if they can predict treatment success.

Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Primary Biliary Cholangitis: Golexanolone Study

We are testing a new medication, golexanolone, for individuals with primary biliary cholangitis who have significant fatigue and cognitive difficulties. The study aims to evaluate its safety and effects on daily life and cognitive function.

Primary Biliary Cholangitis3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesHepatologyInternal Medicine

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Atrial Fibrillation After CABG: Anticoagulant Study

We are studying whether adding anticoagulant medications helps prevent blood clots in patients with new-onset atrial fibrillation after heart surgery. This trial aims to ensure safety and effectiveness in managing this condition.

Atrial FibrillationNew-Onset Post-Operative Atrial Fibrillation after CABG6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Immune Activation: FLAMOD Aerosol Treatment

We are testing a new aerosol treatment to see if it safely activates the immune system. This study aims to understand how well it works in stimulating local immune responses.

Pneumonia6-12 monthsSafety phase (I)Infectious DiseasesPulmonology

Mitral Valve Surgery: Landiolol Study

We are investigating whether Landiolol can help improve heart function and reduce complications after mitral valve surgery. This study looks at its effects on heart health and recovery in patients undergoing this procedure.

Low Cardiac Output Syndrome>2 yearsMonitoring phase (IV)Investigational MedicinesCardiologyInternal Medicine